Consistent inhibitory effects of LRIG1 on both AD and AI (castration-resistant) PCa xenografts as well as in two genetic prostate tumor models prompted us to ask whether LRIG1 might possess therapeutic potential. Here, LRIG1 is linked to prostate neoplasm.